Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: A reasoned and updated guide

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 6, 2011, Pages 601-636

  Cianfrone, Giancarlo ^a   Pentangelo, D ^a   Cianfrone, F ^b   Mazzei, F ^a   Turchetta, R ^a   Orlando, M P ^a   Altissimi, G ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Ototoxicity; Pharmacovigilance; Side effects; Tinnitus; Vertigo

Indexed keywords

CLINICAL PRACTICE; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; OTOTOXICITY; REVIEW; TINNITUS; VERTIGO; VESTIBULAR DISORDER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; HEARING LOSS, SENSORINEURAL; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK; TINNITUS; VERTIGO;

EID: 79960344934     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. CIANFRONE G, RACE M, TURCHETTA R, CIANFRONE F, ALTISSIMI G. An updated guide on drugs inducing ototoxicity, tinnitus and vertigo. Acta Otorhinolaryngol Ital 2005; 25(5 Suppl 81): 3-31.
2. ROSSI F, CUOMO V, RICCARDI C. Farmacologia: principi di base e applicazioni terapeutiche. Ed. Minerva Medica; Torino, 2005.
3. GUIDA ALL'USO DEI FARMACI PER I BAMBINI. Edited by the Italian Ministry of Health. Published by Government Printing Office and Mint State Institute SpA-S., Roma 2003.
4. COMMITTEE ON SAFETY OF DRUG. Report for 1969 and 1970. London, HMSO; 1971.
5. MOORE, TJ, PSATY BM, FURBERG, CD. Time to act on drug safety. JAMA 1998; 279: 1571-1573.
6. BEGAUD B, CHASLERIE A, HARAMBURU F. Organization et rèsultat de la pharmacovigilance en France. Rev Epidèmiol Santè Publique 1994; 42: 416-423.
7. EDWARDS IR. Who cares about pharmacovigilance? Eur J Clin Pharmacol 1997; 53: 83-88.
8. LUMLEY CE, WALKER SR, HALL GC, SRAUNTON N. GROB PR. The under-reporting of adverse reactions seen in general practice. Pharm Med 1986; 1: 205-212.
9. MORIDE Y, HARAMBURU F, REQUEJO AA, BÉGAUD B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-181.
10. DAVIES DM, EDITOR. Textbook of adverse drug reaction. 4th ed, Oxford University Press; 1991.
11. INMAN WHW, EDITOR. Monitoring for drug safety. 2nd ed, Lancaster. MTP Press; 1986.
12. MEYBOOM RHB, EGBERTS ACG, EDWARDS IR, HEKSTER YA, DE KONING FHP, GRIBNAU FWJ. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355-365.
13. SCHACHT J. Biochemical basis of aminoglycoside ototoxicity. Otol Clin North Am. 1993; 26: 845-856.
14. BLACK FO, PESZNECKER SC. Vestibular ototoxicity: Clinical considerations. Otol Clin North Am 1993; 26: 713-736.
15. PRINCE BS, GOETZ CM, RIHN TL, OLSKY M. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49: 1696-1700.
16. SCHNEIDER JH, MION LC, FRENGLEY JD. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90-96.
17. CHRISHILLES EA, SEGAR ET, WALLACE RB. Self-reported adverse drug reactions and related resource use. A study of community-dwelling person 65 years of age and older. Ann Intern Med 1992; 117: 634-640.
18. MOORE N, LECOINTRE D, NOBLET C, MABILLE M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-308.
19. RASCHETTI R, MORGUTTI M, MENNITI-IPPOLITO F, BELISARI A, ROSSIGNOLI A, LONGHINI P, LA GUIDARA C. Suspected adverse drug events requiring emergency department visits or hospital admission. Eur J Clin Pharmacol 1999; 54: 959-963.
20. LAZAROU J, POMERANZ BH, COREY PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
21. EINARSON TR. Drug-related hospital admission. Ann Pharmacother 1993; 27: 832-840.
22. MUEHLBERGER N, SCHNEEWEISS S, HASFORD J. Adverse drug reaction monitoring-cost and benefit considerations, part I. Frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Safety 1997; 6(suppl 3): S71-S77.
23. MAJOR S, BADR S, BAHLAWAN L, HASSAN G, KHOGAOGHLANIAN T, KHALIL R, MELHEM A, RICHANI R, YOUNES F, YERETZIAN J, KHOGALI M, SABRA R. Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations and relation to self-medicating behavior. Clin Pharmacol Ther 1998; 64: 450-461.
24. CLASSEN DC, PESTOTNIK SL, EVANS RS, LYOD JF, BURKE JP. Adverse drug events in hospitalized patients. Excess lenght of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-306.
25. BATES DW, CULLEN DJ, LAIRD N, PETERSEN LA, SMALL SD, SERVI D, LAFFEL G, SWEITZER BJ, SHEA BF, HALLISEY R, VLIET MV, NEMESKAL R, LEAPE LL, HOJNOWSKI-DIAZ P, PETRYCKI S, VANDER VLIET M, COTUGNO M, PATTERSON H, HICKEY M, KLEEFIELD S, COOPER J, KINNEALLY E, DEMONACO HJ, DEMPSEY CLAPP M, GALLIVAN T, IVES J, PORTER K, THOMPSON BT, LAFFEL G, HACKMAN JR, EDMONDSON A. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274: 29-34.
26. LEAPE LL, BATES DW, CULLEN DJ, COOPER J, DEMONACO HJ, GALLIVAN T, HALLISEY R, IVES J, LAIRD N, LAFFEL G, NEMESKAL R, PETERSEN LA, PORTER K, SERVI D, SHEA BF, SMALL SD, SWEITZER BJ, THOMPSON BT, VLIET MV, HOJNOWSKI-DIAZ P, PETRYCKI S, COTUGNO M, PATTERSON H, HICKEY M, KLEEFIELD S, KINNEALLY E, NEMESKAL R, DEMPSEY CLAPP M, LAFFEL G, HACKMAN JR, EDMONDSON A. Systems analysis of adverse drug events. JAMA 1995; 274: 35-43.
27. BATES DW, SPELL N, CULLEN DJ, BURDICK E, LAIRD N, PETERSEN LA, SMALL SD, SWEITZER BJ, LEAPE L. The cost of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-311.
28. BRENNAN TA, LEAPE LL, LAIRD N. Incidence of adverse events and negligence in hospedalized patients: results from the Harvard Medical Practice Study I. N Engl J Med 1991; 324: 370-376.
29. LEAPE LL, BRENNAN TA, LAIRD NM. The nature of adverse drug events in hospitalized patients: results from the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377-384.
30. JOHNSON JA, BOOTMAN JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-1956.
31. GOETTLER M, SCHNEEWEISS S, HASFORD J. Adverse Drug Reaction Monitoring - Cost and benefits considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Safety 1997; 6(suppl. 3): S79-S90.
32. PALOMAR GARCIA V, ABDULGHANI MARTINEZ F, BODET AGUSTI E, ANDREU MENCIA L, PALOMAR ASENJO V. Drug-induced ototoxicity: current status. Acta Otolaryngol 2001; 121: 569-572.
33. VERDEL BM, VAN PUIJENBROEK EP, SOUVEREIN PC. Drug-related nephrotoxic and ototoxic reactions: a link through a predictive mechanistic commonality. Drug Safety 2008; 31: 877-884.
34. MICK P, WESTERBERG BD. Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol 2007; 36: 257-263.
35. ROTH SM, WILLIAMS SM, JIANG L, MENON KS, JEKA JJ. Susceptibility genes for gentamicin-induced vestibular dysfunction. J Vestib Res 2008; 18: 59-68.
36. KNOLL C, SMITH RJ, SHORES C, BLATT J. Hearing genes and cisplatin deafness: a pilot study. Laryngoscope 2006; 116: 72-74.
37. KITAMURA K, TAKAHASHI K, TAMAGAWA Y, NOGUCHI Y, KUROISHIKAWA Y, ISHIKAWA K, HAGIWARA H. Deafness genes. J Med Dent Sci 2000; 47: 1-11.
38. PETERS U, PREISLER-ADAMS S, LANVERS-KAMINSKY C, JURGENS H, LAMPRECHT- DINNESEN A. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 2003; 23(2B): 1249-1255.
39. OLDENBURG J, FOSSÀ SD, IKDAHL T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 2008; 9: 1521-1530.
40. BINDU LH, REDDY PP. Genetics of aminoglycoside-induced and prelingual non-syndromic mitochondrial hearing impairment: a rewiew. Int J Audiol 2008; 47: 702-707.
41. BLAKLEY BW, HOCHMAN J, WELLMAN M, GOOI A, HUSSAIN AE. Differences in ototoxicity across species. J Otolaryngol Head Neck Surg 2008; 37: 700-703.
42. BERENHOLZ LP, BURKEY JM, FARMER TL, LIPPY WH. Topical otic antibiotics: clinical cochlear ototoxicity and cost consideration. Otolaryngol Head Neck Surg 2006; 135: 291-294.
43. PAPPAS S, NIKOLOPOULOS TP, KORRES S, PAPACHARALAMPOUS G, TZANGARULAKIS A, FEREKIDIS E. Topical antibiotic ear drops: are they safe? Int J Clin Pract 2006; 60: 1115-1119.
44. FAUSTI SA, FREY RH. Portable stimulus generator for obtaining high-frequency (8-14 Khz) auditory brainstem responses. J Am Acad Audiol 1992; 3: 166-175.
45. FAUSTI SA, FREY RH, HENRY JA, OLSON DJ, SCHAFFER HI. High-frequency testing techniques and instrumentation for early detection of ototoxicity. J Rehabil Res Dev 1993; 30: 333-341.
46. FAUSTI SA, HENRY JA, HELT WJ. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 1999; 20: 497-505.
47. HANDLESMAN JA, KONRAD-MARTIN D. Monitoring ototoxic changes in auditory and vestibular systems; 2005. http//www.ncrar.research.va.gov/AboutUs/Staff/D ocuments/ototoxic-changes.pdf
48. KONRAD-MARTIN D, GORDON JS. Monitoring for ototoxicity-induced hearing loss; 2005. http//www.ncrar.research.va.gov/About Us/Staff/ Documents/ototoxic- changes.pdf
49. BERTOLINI P, LASSALLE M, MERCIER G, RAQUIN MA, IZZI G, CORRADINI N, HARTMANN O. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
50. LEVISON ME. New dosing regimens for aminoglycoside antibiotics. Ann Intern Med 1992; 117: 693-694.
51. PREZANT TR, AGAPIAN JV, BOHLMAN MC, BU X, OZTAS S, QIU WQ, ARNOS KS, CORTOPASSI GA, JABER L, ROTTER JI, SHOHAT M, FISCHEL-GHODSIAN N. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genetics 1993; 4: 289-294.
52. USAMI S, ABE S, TONO T, KOMME S, KIMMERLING WJ, SHINKAWE H. Isepamicin sulfate-induced sensorineural hearing loss patients with the 1555 A-G mitochondrial mutation. ORL 1998; 60: 164-169.
53. USAMI S, HJELLE OP, OTTERSEN OP. Differential cellular distribution of glutathione - an endogenous antioxidant - in the guinea pigs inner ear. Brain Res 1996; 743: 337-340.
54. ESTIVILL X, GOVEA N, BARCELÓ E, BADENAS C, ROMERO E, MORAL L, SCOZZRI R, D'URBANO L, ZEVIANI M, TORRONI A. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 1998; 62: 27-35.
55. FISHEL-GODSIAN N, PREZANT TR. Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. Am J Otolaryngol 1993; 14: 339-403.
56. GUAN MX, FISHEL-GODSIAN N, ATTARDI G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000; 9: 1787-1793.
57. USAMI S, ABE S, KASAI M, SHINKAWA H, MOELLER B, KENYON JB, KIMBERLING WJ. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. Laryngoscope 1997; 483-490.
58. MATSUNAGA T, KUMANOMIDO H, SHIROMA M, OHTSUKA A, ASAMURA K, USAMI S. Deafness due to A1555 G mitochondrial mutation without use of aminoglycoside. Laryngoscope 2004; 114: 1085-1091.
59. DENOYELLE F, MARLIN S. Surdité de perception d'origine génétique. Traité EMC 2005; 20-191-A- 10.
60. HARTWIG S, SIEGEL J, SCHNEIDER P. Preventability and severity assessment in reporting adverse drug reactions. AM J Hosp Pharm 1992; 49: 2229-2232.